Proteo Biotech AG

Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension

Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)

Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants – convincing preclinical evidence in a neonatal pulmonary model

Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)

Proteo, Inc. / Proteo Biotech AG: Major advances in the elafin development program for lung diseases – NIH supports research on Elafin with a $10.8 million grant

Proteo, Inc. / Proteo Biotech AG: EMPIRE-Studie schließt erste Koronarbypass-Patienten ein